The effects of reformulated 2-rod Norplant® implant on hemostasis after three years

Contraception

Volumn 54, Issue 4, 1996, Pages 219-228

  Viegas, O A C ^a   Koh, S C L ^a   Ratnam, S S ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

hemostasis; reformulated Norplant

Indexed keywords

LEVONORGESTREL;

ADULT; ARTICLE; CONTRACEPTION; CORONARY RISK; DRUG EFFECT; DRUG FORMULATION; FEMALE; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HEMOSTASIS; HUMAN; NORMAL HUMAN;

EID: 0030273340     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(96)00192-8     Document Type: Article

References (19)

1. 1. Inman WHW, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroid content of oral contraceptives. A report to the committee on safety of drugs. Br Med J 1970;2:203-9.
2. 2. Bottiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease. Effects of lowering oestrogen content. Lancet 1980;i:1097-101.
3. 3. Royal College of General Practitioners. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet 1977;i: 624.
4. 4. Kay CR. Progestogens and arterial disease - evidence from the Royal College of General Practitioner's study. Am J Obstet Gynecol 1982;142:762-5.
5. 5. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50μg or 30 μg oestrogen preparations. Br Med J 1980;282:1157-61.
6. 6. Porter JB, Jick H, Walker AM. Mortality among oral contraceptive users. Obstet Gynecol 1987;70:29-32.
7. 7. Diaz S, Pavez M, Miranda P, Robertson DN, Sivin I, Croxatto HB. A five-year clinical trial of levonorgestrel Silastic implants (Norplant™). Contraception 1982;25: 447-56.
8. 8. Singh K, Viegas OAC, Ratnam SS. Evaluation of haemostatic function following Norplant-2 rod removal. Adv Contracep 1993;9:241-50.
9. 9. Setiabudy RD, Affandi B, Witjaksono B, Wiranam R, Hendratna M, Hidayat E. The effect of Norplant on some haemostatic parameters in Indonesian women. South-East Asian J Trop Med Publ Health 1993; 24(suppl 1):234-6.
10. 10. Koh CLS, Yuen R, Viegas OAC, et al. A plasmin generation method for the determination of tissue plasminogen activator (t-PA) activity in blood. Immunol Cell Biol 1989;67:197-203.
11. 11. Koh CLS, Yuen R, Viegas OAC, et al. Plasma tissue plasminogen activator inhibitor (t-PAI) activity in normal subjects. Med Sci Res 1989;17:135-6.
12. 12. Koh SCL, Yuen R, Viegas OAC, Ratnam SS. Plasma urokinase activity and antigen levels in normal males, females and in late pregnancy. Med Sci Res 1992;20: 601-2.
13. 13. Clauss A. Gerinnungs physiologische schnell methods zur bestimmunig des fibrinogens. Acta Haematol 1957; 17:237-46.
14. 14. Shaaban MM, Elwan SI, EL-Kabshmy, Farghaly SA, Thabet N. Effect of levonorgestrel contraceptive implants Norplant® on blood coagulation. Contraception 1984;30:421-30.
15. 15. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Ca Res 1985;44:139-266.
16. 16. Kjaeldgaard A, Ahlesteen I, Larsson B, Astedt B. Progestogen regulation of tissue plasminogen activator in a melanoma cell line. Thromb Res 1988;49:287-97.
17. 17. Meade TW, Brozovic M, Chakrabathi RR, et al. Haemostatic functions and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;ii:533-7.
18. 18. Hoffmann C, Miller R, Lawson W, Hutin M. Elevation of Factor VII activity and mass in young adults at risk of ischaemic heart disease. J Am Coll Cardiol 1989;14: 941-6.
19. 19. Ernst E. Plasma fibrinogen - an independent cardiovascular risk factor. J Intern Med 1990;227:365-72.